Identiv, Inc. announced the appointment of Laura Angelini and Richard Kuntz, MD, MSc. to its Board of Directors. Both Directors bring unique medical industry expertise to the Board, an industry that is recognized as one of the largest global market opportunities for Identiv IoT products and services.

The new board members' experience managing disciplined, global operations for large, multinational healthcare companies, and integrating leading edge technology into their operational processes, will be strategically invaluable to Identiv's growth plans in this important market. Laura Angelini was appointed General Manager, Global Business Unit, Renal Care at Baxter Healthcare International in 2016 after serving as the Global Platform Leader, Joints, at DePuy Synthes Companies of Johnson & Johnson. During her 25-year tenure with Johnson & Johnson Angelini led organizations across Europe and North America, managing exponential acceleration in MedTech.

She scaled businesses across global functions, led strategy design for profitability and market leading performance, and created innovation strategies for digital transformation. She stepped down from her position with Baxter in 2021, and currently serves as a non-executive Director and Member of the Governance and Sustainability Committee and of the Remuneration Committee of the Board of Directors of DCC plc and a Member of the Board of Trustees and the Audit and Compliance Committeeof Jacksonville University. Ms. Angelini received her degree in Foreign Languages & Literatures from University La Sapienza.

Dr. Richard E. Kuntz joins the board following his most recent role as Senior Vice President and Chief Medical and Scientific Officer with Medtronic, the leading global healthcare technology company addressing the most challenging health problems. He has more than 20 years' experience as a leader in MedTech, including his previous role as President of Medtronic Neuromodulation. Prior to Medtronic, Dr. Kuntz worked as an Associate Professor, Medicine, and Chief, Clinical Biometrics at Harvard Medical School. He is the Founder and former Chief Scientific Officer of the Harvard Clinical Research Institute.

He received his MD from Case Western Reserve University and his MS, Biostatistics from Harvard University, and holds two medical patents. Dr. Kuntz is a Non-executive Director of the ZimVie board, a global life science leader in the dental and spine markets. Directors Nina Shapiro and Robin Braun will retire from the Board this month.